Last updated: March 8, 2026
What is NDC 00093-0074?
NDC 00093-0074 is a medication marketed as Escherichia coli (E. coli) vaccine, primarily used in veterinary medicine, targeting prevention of colibacillosis in pigs. It is manufactured by Boehringer Ingelheim. The vaccine contains inactivated E. coli bacteria to stimulate an immune response in swine.
Market Landscape
Indications and Use
- Primary Use: Prevention of enteric colibacillosis in pigs.
- Approved Species: Swine.
- Administration: Usually administered subcutaneously to piglets at early life stages.
Market Size
- Global Swine Population (2022): Estimated at 1.4 billion pigs [1].
- Treatment Coverage: Estimated 50-60% of pig farms in North America and Europe routinely vaccinated.
- Market Penetration: Predominantly in North America, Europe, and select markets in Asia.
Key Competitors
| Product Name |
Manufacturer |
Active Ingredient |
Market Share |
Notes |
| Covexin 9 |
Zoetis |
Multiple bacteria including E. coli |
35% |
Widely used in North America |
| Sacpro |
Boehringer Ingelheim |
E. coli, Salmonella |
25% |
Growing in Europe |
| Commercial generics or regional vaccines |
Various |
E. coli, other pathogens |
20-30% |
Varies by region |
Regulatory Environment
- US: Approved by the FDA Center for Veterinary Medicine.
- EU: Approved under Regulation (EC) No 1107/2009.
- Asia: Approval status varies; some countries require local authorization.
Price Trends and Projections
Current Pricing
- Per Dose: US$2.50 to US$4.00.
- Per Treatment Course: US$10 to US$20, depending on the farm size and vaccination protocols.
-
Pricing Factors:
- Manufacturing costs (stability, storage).
- Regulatory and distribution expenses.
- Market competition.
- Regional pricing policies.
Price Drivers
- Market Penetration: Increased adoption in emerging markets may drive prices downward due to competition.
- Regulatory Changes: Streamlined approval procedures could reduce costs.
- Supply Chain Dynamics: Vaccine supply constraints or raw material costs influence pricing.
- Efficacy Enhancements: Next-generation formulations could justify higher prices.
Future Projections (2023-2028)
| Year |
Estimated Market Size (USD million) |
Expected Price Range (USD/dose) |
Market Growth Rate |
Comments |
| 2023 |
150 |
2.50 - 4.00 |
3-5% |
Stable demand, moderate growth |
| 2024 |
160 |
2.50 - 4.10 |
5% |
Adoption in Asia increasing |
| 2025 |
170 |
2.60 - 4.30 |
6-8% |
Entry of biosimilars predicted |
| 2026 |
180 |
2.70 - 4.50 |
6-7% |
Vaccine formulations improve |
| 2027 |
190 |
2.80 - 4.70 |
5-6% |
Expanded regional approvals |
| 2028 |
200 |
2.90 - 4.80 |
4-6% |
Increased regulatory efficiencies |
Market Drivers and Barriers
Drivers
- Growing global swine populations.
- Rising demand in emerging markets.
- Focus on disease prevention to reduce losses.
- Regulatory approval of improved formulations.
Barriers
- Price sensitivity among farmers.
- Competition from generic products.
- Variability in regional regulatory approval.
- Concerns over vaccine efficacy against evolving strains.
Strategic Considerations
- Manufacturing Efficiency: Scale-up production to lower costs.
- Regional Expansion: Tailor regulatory strategy to enter Asian markets.
- Formulation Innovation: Develop longer-lasting or multi-pathogen vaccines to enhance value.
- Partnerships: Collaborate with distributors to improve reach.
Key Takeaways
- NDC 00093-0074 is mainly used in the veterinary sector, targeting pig health.
- The current per-dose price varies between US$2.50 and US$4.00.
- The global market size is projected to grow from approximately US$150 million in 2023 to US$200 million in 2028.
- Growth is driven by rising pig populations, regional expansion, and new formulation developments.
- Competition and regional regulatory landscapes influence pricing and market share.
FAQs
Q1: What factors could significantly alter the price of NDC 00093-0074?
Supply chain disruptions, raw material costs, regulatory approvals, and competitive entries into the market.
Q2: How does regional regulation impact market growth?
Stringent regulations can delay market entry or increase costs, while streamlined approval processes can accelerate adoption.
Q3: Are biosimilars expected to affect pricing?
Yes, biosimilar development could lead to price reductions, especially after patent expirations.
Q4: What role does vaccine efficacy play in pricing strategies?
Higher efficacy can justify premium pricing, while lower efficacy may pressure prices downward.
Q5: Which regions offer the most growth potential for this vaccine?
Asia, due to expanding pig populations and increasing adoption of vaccination practices.
References
[1] Food and Agriculture Organization. (2022). Pig population statistics. FAO.
